I have reviewed the panel files, curation notes, method outputs, and the figures, and produced the requested deliverables in your workdir.

What I did
- Examined coverage summary and grouped panel to map capabilities and identify risks/gaps.
- Inspected UMAPs and RF confusion matrices to assess lineage/state separability and malignant-vs-other performance.
- Cross-checked select lineages/states against the final_panel_1000.csv.
- Collected concise literature-backed notes for sentinel genes.

Deliverables
- Interpretation report: /home/erwinpi/pantheon-agents/examples/gene_panel_selection/cases/gene_panel_selection_immune/workdir/biologist/interpretation_final_panel.md
- Proposed adjustments (≤20 genes): /home/erwinpi/pantheon-agents/examples/gene_panel_selection/cases/gene_panel_selection_immune/workdir/biologist/proposed_adjustments.csv
- Supporting sentinel gene notes with links: /home/erwinpi/pantheon-agents/examples/gene_panel_selection/cases/gene_panel_selection_immune/workdir/biologist/report_browser_use_tme_sentinel_genes.md
- BibTeX: /home/erwinpi/pantheon-agents/examples/gene_panel_selection/cases/gene_panel_selection_immune/workdir/biologist/references_1.bib

Executive summary (high-level)
- Coverage: The 1000-gene panel robustly captures TME lineages (T/NK/B/plasma; myeloid/DC/neutrophil), exhaustion/activation axes, antigen presentation, malignant vs immune segregation, major cancer signalling pathways (RTK/MAPK/PI3K/JAK-STAT/TGF-β/WNT), and stress programs (cell cycle, DDR, UPR/heat-shock, hypoxia/angiogenesis, EMT/ECM/vasculature). UMAPs using only the panel show good lineage/state separation. RF confusion for fine cell types shows expected errors among closely related subsets.
- Risks/gaps: Several interleukins are very lowly expressed in this dataset (risking spatial detectability). Some paralog families (TCR/BCR constants, KRTs, S100s, HLA class I, WNT/FZD) carry cross-hybridization risk and warrant probe specificity checks. DC/neutrophil anchors could be reinforced for spatial disambiguation. The malignant-vs-other RF failure appears to be a model/training issue (all predicted as “Other”) rather than a panel deficiency, as UMAPs show separability.
- Adjustments (≤20): I proposed 12 adds (myeloid/DC/neutrophil anchors; adenosine and ligand checkpoints) and 8 drops (low-yield interleukins and a few redundant paralogs) to improve robustness while keeping scope minimal.

Summary of proposed adjustments (see CSV for details)
- Add: ITGAX, MRC1, FCGR3B, MPO, CD1C, ENTPD1 (CD39), NT5E (CD73), PDCD1LG2 (PD-L2), CD274 (PD-L1), ICOSLG, CCR8, CLEC4C.
- Drop: IL9, IL13, IL22, IL37 (very low expression here); TRBC1 (retain TRBC2), IGLC3 (retain IGKC/IGLC2), WNT1, WNT7A (retain pathway readouts via WNT5A/CTNNB1/FZDs/DKK1).

Notes on figures
- UMAPs: Clear, coherent separation for broad and fine cell types with the panel alone.
- Malignant vs other RF: All calls “Other” suggests training/label imbalance or setup issue; not a coverage failure per se.
- RF cell-type confusion: Good for common classes; misclassifications cluster among biologically similar subtypes; rare classes underperform (expected).

20 sentinel genes with brief rationale and references
- Included in interpretation_final_panel.md (with GeneCards/UniProt links). The set: CD3E, TRAC, PRF1, GZMB, PDCD1, HAVCR2, FOXP3, IL2RA, MS4A1, MZB1, LST1, FCGR3A, CLEC9A, CXCL13, PECAM1, KDR, COL1A1, EPCAM, EGFR, MKI67.

Recommendations for analysis workflow
- Re-train malignant vs other with class weighting/stratified CV; verify labels and feature scaling. Try simpler linear baselines to sanity-check.
- For spatial deployment, run probe-uniqueness checks for paralog families and validate detectability of lowly expressed cytokines on a pilot run; apply the provided swap list if needed.

Please see the full write-up and actionable CSV in the biologist directory paths above.